Kura Oncology Reports First Patient Dosing of Ziftomenib in P-II (KOMET-001) Registration-Directed Trial for NPM1-Mutant Acute Myeloid Leukemia
Shots:
- The first patients have been dosed in the P-II (KOMET-001) registration-directed trial evaluating ziftomenib (menin inhibitor) in 199 patients
- The 1EPs of the study are CR or CR with hematologic recovery & the 2EPs incl. clinical benefit, safety & tolerability. As the data cutoff on Oct 2022 in the P-I trial, ziftomenib showed a 30% CR rate in 20 NPM1-mutant AML patients treated at 600mg along with a favorable safety profile with an encouraging tolerability
- The company plans to initiate the (KOMET-007 & 008) in 2023 to evaluate ziftomenib + SoC in earlier lines of therapy and across multiple patient populations, incl. NPM1-mutant and KMT2A-rearranged AML
Ref: Kura Oncology | Image: Kura Oncology
Related News:- Kura Oncology Reports the US FDA's Clinical Hold on the P-Ib Study of KO-539 for the Treatment of Acute Myeloid Leukemia
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
